Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease
Articles > Review · 2018
Authors: Ilgın YILDIRIM ŞİMŞİR, UTKU ERDEM SOYALTIN, Şevki ÇETİNKALP
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, Journal Indexed in SCI Expanded, International, 2018, vol 12, pp 469-475
DOI: 10.1016/j.dsx.2018.03.002
Summary
Glucagon-like peptide-1 (GLP-1) is a 30 amino acid long peptide hormone derived from the proglucagon geneandsecreted in the distal smallintestine when food enters the duodenum. GLP-1 is also produced in the central nervous system (CNS), predominantly in the brainstem, and subsequently transported to a large number of regions in the CNS. Neuronal cells in nucleus tractus solitarius (NTS) can synthesize GLP-1 and extends to hypothalamus, some thalamic and cortical areas. A G protein coupled receptor (GPCR) provides the majority of GLP-1 actions. GLP-1 receptor activation triggers some in vivo signaling pathways. GLP-1 receptor agonists (GLP-1 RA) are used in the treatment diabetes and obesity.